Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea

Abu Rachman¹, Rani Sauriasari*, Nadia Farhanah Syafhan¹, Pukovisa Prawiroharjo², Hindun Wilda Risni¹

¹Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia, ²Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Abstract
The most prescribed antidiabetic drugs in Indonesian primary health care are metformin or a combination of metformin and sulfonylurea. Studies on metformin have shown various impacts on cognitive decline in patients with type 2 diabetes mellitus, whereas sulfonylurea has been shown to reduce this impact. This study aimed to compare the impacts of metformin and metformin-sulfonylurea on cognitive function and determine what factors affected it. This cross-sectional study was conducted at Pasar Minggu Primary Health Care involving 142 type 2 diabetes mellitus patients taking metformin or metformin-sulfonylurea for >6 months and aged >36 years. Cognitive function was assessed using the validated Montreal Cognitive Assessment Indonesian version. The effects of metformin and metformin-sulfonylurea on cognitive decline showed no significant difference, even after controlling for covariates (aOR = 1.096; 95% CI = 0.523–2.297; p-value = 0.808). Multivariate analysis showed age (OR = 4.131; 95% CI = 1.271–13.428; p-value = 0.018) and education (OR = 2.746; 95% CI = 1.196–6.305; p-value = 0.017) affected cognitive function. Since a lower education and older age are likely to cause cognitive decline, health professionals are encouraged to work with public health experts to address these risk factors for cognitive function.

Keywords: cognitive decline, cognitive function, diabetes mellitus, metformin, metformin-sulfonylurea

Introduction
Indonesia has 10.7 million people with diabetes mellitus (2% of its population), ranking it seventh in the world.¹ Type 2 diabetes mellitus (T2DM) is a metabolic disease that can cause various complications. Patients with diabetes mellitus (DM) have a one-and-a-half-fold risk of decreased cognitive function compared to those without it.² Declines in cognitive function interfere with self-care management behaviors, such as adherence to medication, seeking proper care, glycemic control,³ and managing the adverse effects of diabetes medications.⁴-⁶ Various antidiabetic drugs have been evaluated and investigated for their relationship with cognitive function. Metformin is the first line of antidiabetic therapy and is often used alone or in combination with sulfonylurea.⁷ Studies that have examined the effects of metformin on cognitive function have yielded different results.⁸,⁹ One study showed that metformin could have a protective effect on cognitive function.⁹ Another study showed that metformin causes cognitive decline by creating amyloid plaques in the brain,¹⁰ and B12 deficiency.⁵ Another antidiabetic drug, sulfonylurea, was found to reduce the occurrence of cognitive decline in patients with DM.⁴ However, another study among diabetic patients found that sulfonylureas increase the risk of hypoglycemia, which increases the risk of cognitive decline.¹¹ While, the combined use of metformin-sulfonylurea was able to reduced cognitive decline and dementia.¹² Further study should be conducted due to the limited evidence of the effects of the combination of metformin and sulfonylureas on cognitive function.

Although T2DM patients are at high risk for cognitive decline, cognitive function assessments are rarely performed. People with cognitive decline are at risk of having other advanced neurocognitive disorders that can increase the public health burden.¹³ Therefore, cognitive assessments can help health care providers address this problem. In addition, considerations in choosing only metformin or a combination need to include comprehensive assessments to optimize therapy for T2DM patients. Aside from drug indications, the effects of medications on cognitive function are of paramount importance in
therapy considerations. Moreover, it is important to explore other factors that can exacerbate declines in cognitive function so that appropriate intervention steps can be taken. Therefore, this study aimed to compare the effects of metformin and a combination of metformin-sulfonylurea on cognitive function and investigated other factors affecting cognitive function.

**Method**

This cross-sectional study was conducted at Pasar Minggu Primary Health Care in South Jakarta, Indonesia. Data collection took place between October and December 2021. The T2DM patients of Pasar Minggu Primary Health Care could participate in the study if they met the inclusion criteria, were not disqualified by the exclusion criteria, were willing to be interviewed, and signed an informed consent form. A total of 142 T2DM patients were included in this study. The minimum sample size was calculated using the formula in Formula 1. The minimum sample size was 49 participants per group with a \( P_1 \) value of 0.67 and a \( P_2 \) value of 0.35.

All samples in this study were taken from T2DM patients treated at the outpatient polyclinic for noncommunicable diseases at Pasar Minggu Primary Health Care. The data collection process was carried out via a consecutive sampling method. The participants in this study were selected based on the inclusion criteria: T2DM patients who used metformin alone or a combination of metformin and sulfonylurea for at least six months and aged 36 years and over. Metformin was primarily indicated for patients with an HbA1c value of less than 7.5%, while metformin-sulfonylurea was mainly given to patients with an HbA1c value of more than 7.5% or if monotherapy for three months resulted in an HbA1c value of more than 7%.

The participants in their late adulthood were selected to distinguish the study subjects from type 1 diabetes mellitus (T1DM) patients, who are generally younger. Patients were then disqualified based on the exclusion criteria: used insulin, could not read or write, had difficulty in communicating, had mental disorders, diagnosed with dementia, and had mild depression as measured using the Indonesian version of the Beck Depression Inventory-II (BDI-II) questionnaire to reduce confounding factors that could affect the study variables. A flowchart of the participants’ selection is shown in Figure 1.

The outcome of this study was cognitive function. Cognitive function refers to problem-solving, learning, thinking, using stored information appropriately, remembering, and paying attention. Cognitive function testing was carried out using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), which was previously validated. Participants were considered to have not experienced a decline in cognitive function if they had a score \( \geq 26 \).

Patients who met the inclusion criteria were given the BDI-II questionnaire translated into the Indonesian language, which met validity and reliability tests. Patients with a BDI-II score above 17 were declared to have mild depression. Based on the results of the BDI-II questionnaire, none of the patients in this study had mild depression. Patient demographic data were collected through

\[
n = \frac{\left( \frac{Z_{1-\alpha/2}}{2} \right)^2 (\frac{1}{\alpha_1} + \frac{1}{\alpha_2})}{\left( \frac{P_1}{1-P_1} + \frac{P_2}{1-P_2} \right)^2}
\]

**Formula 1. Sample Size**

Notes:
- \( Z_{1-\alpha/2} \) = the normal standard deviation (SD) (5% for type 1 error [p-value<0.05] is 1.96)
- \( Z_1-\beta \) = the normal SD for 90% power (10% for type 2 error is 1.2816)
- \( P = \frac{P_1 + P_2}{2} \)
- \( P_1 \) = the proportion of patients using metformin with cognitive decline
- \( P_2 \) = the proportion of patients using metformin-sulfonylurea with cognitive decline

![Flowchart of Participants' Selection](image-url)
Peripheral blood samples were taken to observe medical records (the use of drug therapy, weight, height, duration of DM, and disease comorbidities) and interviews with a questionnaire (age, sex, education, and smoking record).

Adherence was assessed by combining two measurement tools, the Indonesian version of the Adherence to Refills and Medications Scale (ARMS) and the proportion of days covered (PDC). 21, 22 The participants were interviewed using the ARMS questionnaire. The PDC data were based on patients’ visits over the last six months through the e-Puskesmas (an electronic system of patients’ visits to primary health care). 22, 23 Patients were considered adherent if their ARMS score was less than 12 and their PDC value was ≥80%. All the questionnaires (the Indonesian versions of ARMS, BDI-II, and the MoCA) had been through a translation and back-translation process were then tested for validity and reliability. 18, 20, 21 Peripheral blood samples were taken to measure HbA1c levels using the Abbott Afinion™ instrument. Hypertension and dyslipidemia were documented based on doctors’ written statements in medical records, which means that the criteria for hypertension and dyslipidemia were not determine. Patients were considered smokers if they were current smokers at the time of the interview.

A comparison of the effects of metformin only and metformin-sulfonylurea on cognitive function was conducted. Univariate analysis was performed to describe patient’s characteristics. To compare the impacts of the therapies on cognitive function, a Chi-square test was performed, where a p-value of <0.05 was considered significant. Variables with a p-value of <0.25 in the bivariate test or that theoretically had a significant effect on the function were included in the logistic regression. Logistic regression was used to control for confounding variables, and the last model was chosen based on the smallest precision value among all the models. To further identify the variables affecting cognitive function, predictive logistic regression using the backward elimination method was conducted. The variables were selected for the same reason as in the first logistic regression (control for variables). Variables with p-value<0.05 in the last model were considered factors affecting cognitive function. The data are expressed in proportions (n, %) for categorical variables and median (min-max) for numerical variables. The data analysis was conducted using the Statistical Package for the Social Sciences (SPSS) version 28.0 (IBM SPSS Statistics Grad Pack 28.0 for Windows or Mac; IBM Corp., Armonk, New York, USA).

Results

The participants in this study consisted of 142 T2DM patients at Pasar Minggu Primary Health Care. Females outnumbered males in each group, with 54 females (76.05%) in the metformin group and 55 males (77.47%) in the metformin-sulfonylurea group. There was a significant difference between the groups in terms of education (p-value = 0.044), as patients with more than 12 years of education were more dominant in the metformin group. Significant differences between groups were also seen in patients’ HbA1c levels (p-value = 0.005), ARMS scores (p-value = 0.018), levels of adherence (p-value = 0.075), and vitamin B12 supplementation (p-value = 0.022). The mean age was 59.27 years (SD = 9.2) in the metformin group and 57.90 years (SD = 7.5) in the metformin-sulfonylurea group. There were no significant differences between the groups in age (p-value = 0.555), sex (p-value = 1.000), duration of diabetes (p-value = 0.065), PDC score (p-value = 0.707), body mass index (BMI) (p-value = 0.491), duration of drug consumption (p-value = 1.000), hypertension (p-value = 1.000), dyslipidemia (p-value = 0.595), or smoking (p-value = 1.000). The characteristics of the participants are shown in Table 1.

The participants who experienced a decline in cognitive function significantly outnumbered those who did not (66.90%; 95/142). The proportion of patients aged less than 65 years with normal cognitive function was significantly higher than that of patients aged older than 65 years (p-value = 0.022). Significantly different results were also found in terms of compliance (p-value = 0.024). Although a decline in cognitive function was predominantly observed among females, 71 (74.7%) patients, the difference between the sexes was insignificant. Differences in HbA1c levels were also insignificant despite participants with HbA1c levels of ≥7 being more likely to experience a decline in cognitive function. Education, duration of DM, ARMS score, PDC score, duration of drug consumption, vitamin B12 supplementation, BMI, hypertension, dyslipidemia, and smoking did not significantly increase the odds of cognitive decline (Table 2).

The metformin-sulfonylurea group had more participants who experienced cognitive decline than the metformin group. In the metformin group, the proportion of patients with decreased cognitive function was 63.4%, while that of patients with normal cognitive function was 36.6%. In the metformin-sulfonylurea group, 70.4% of the patients experienced decreased cognitive function. However, there was no significant difference between the two groups (OR = 1.376; 95% CI = 0.682–2.776; p-value = 0.373) (Table 3). To control confounding variables, a multivariate analysis was performed using logistic regression. Bivariate analysis was conducted to select variables that had p-value<0.25, which were age, education, adherence based on the ARMS questionnaire, and comorbid hypertension (Table 2). Sex, HbA1c, B12
supplementation, and BMI were still included in the multivariate analysis because they substantially affected cognitive function. The effect of cognitive function remained insignificant after controlling for confounding variables (Table 4).

Table 5 shows the last model of multivariate analysis using the predictive model. It shows that age (OR = 4.131; 95% CI = 1.271–13.428; p-value = 0.017) and education (OR = 2.746; 95% CI = 1.196–6.305; p-value = 0.018) affected cognitive function.

Discussion

Metformin is an antidiabetic drug widely used alone or in combination with sulfonylurea. Both regimens can affect cognitive function, either positively or negatively. In this study, the participants were predominantly females because they suffered from T2DM at a higher rate than males. Interestingly, males were 35.2% more at risk of experiencing cognitive decline than females, which is in line with the previous study. However, a study found that women tend to experience more cognitive decline than men. Therefore, more study is needed on sex and cognitive decline.

Participants who suffered from T2DM for less than five years used metformin more (64.8%) than participants who suffered from T2DM for more than five years (53.2%). Participants with a T2DM duration of more than five years used metformin-sulfonylurea (39%) more than metformin only (47.9%). This condition was caused by uncontrolled blood sugar levels in more participants, so that the treatment target was not reached. The antidiabetic medicines of those patients were combined with therapy, following the guidelines which recommended metformin as the first line of antidiabetic therapy. If a patient’s HbA1c value is more than 7.5% or more than 7%, then metformin-sulfonylurea will be prescribed with a different mechanism.
Table 2. Factors Increasing the Odds of Cognitive Function Decline

| Variable                      | Category          | Cognitive Function | OR (95% CI) |
|-------------------------------|-------------------|--------------------|-------------|
|                               | (n = 95)          | (n = 47)           |             |
| Age, year                     | Mean±SD           | 56.06±6.7          | 59.83±8.9   | 0.011        | 1.214 (0.682–2.776) |
| Age, n (%)                    | ≥65 years old     | 67 (70.5)          | 42 (89.4)   | 0.022        | Ref            |
|                               | >65 years old     | 28 (29.5)          | 5 (10.6)    | 3.510 (1.257–9.801) |
| Sex, n (%)                    | Male              | 24 (25.3)          | 9 (19.1)    | 0.548        | Ref            |
|                               | Female            | 71 (74.7)          | 38 (80.9)   | 0.701 (0.296–1.658) |
| Education, n (%)              | >12 years         | 43 (45.3)          | 30 (63.8)   | 0.057        | Ref            |
|                               | ≥12 years         | 52 (54.7)          | 17 (36.2)   | 2.134 (1.040–4.381) |
| HbA1c, %                      | Mean ± SD         | 8.3±0.9            | 8.2±0.1     | 0.896        | Ref            |
| HbA1c level, n (%)            | HbA1c<7           | 24 (25.3)          | 9 (19.1)    | 0.548        | Ref            |
|                               | HbA1c≥7           | 71 (74.7)          | 38 (80.9)   | 0.701 (0.296–1.658) |
| Duration of DM, n (%)         | ≤5 years          | 30 (32.6)          | 30 (63.8)   | 0.277        | Ref            |
|                               | >5 years          | 45 (47.4)          | 17 (36.2)   | 1.588 (0.774–3.258) |
| ARMS                           | <12               | 35 (36.8)          | 26 (55.3)   | 0.062        | Ref            |
|                               | ≥12               | 60 (65.2)          | 21 (55.3)   | 2.087 (1.025–4.249) |
| Proportion of days covered (PDC) | ≥80%              | 70 (73.7)          | 33 (70.2)   | 0.813        | Ref            |
| Adherence, n (%)              | Adherent          | 25 (26.3)          | 14 (29.8)   | 0.842 (0.388–1.826) |
|                               | Non-adherent      | 70 (73.7)          | 25 (53.2)   | 0.024        | Ref            |
| Duration of drug consumption, n (%) | <12 months       | 2 (2.1)            | 3 (6.4)     | 0.414        | Ref            |
|                               | ≥12 months        | 93 (97.9)          | 44 (93.6)   | 3.170 (0.311–19.661) |
| Vitamin B12 supplementation   | Yes               | 67 (70.5)          | 38 (80.9)   | 0.264        | Ref            |
|                               | No                | 28 (29.5)          | 9 (19.1)    | 1.765 (0.754–4.126) |
| BMI, kg/m²                    | Mean±SD           | 27.27±4.3          | 26.34±4.7   | 0.254        | Ref            |
| BMI in category, n (%)        | Skinny–normal (<25) | 38 (40.0)      | 17 (36.2)   | 0.797        | 0.850 (0.413–1.751) |
|                               | Overweight–obese (>25) | 57 (60.0)   | 30 (63.8)   | 7.979        | 1.635 (0.963–3.991) |
| Hypertension                  | No                | 33 (34.7)          | 24 (51.1)   | 0.092        | Ref            |
|                               | Yes               | 62 (65.3)          | 23 (48.9)   | 0.960        | Ref            |
| Dyslipidemia                  | No                | 65 (68.4)          | 29 (61.7)   | 0.543        | Ref            |
|                               | Yes               | 45 (46.4)          | 49 (69.0)   | 1.345 (0.648–2.791) |
| Smoker                        | No                | 89 (93.7)          | 46 (97.9)   | 0.501        | 3.101 (0.362–26.535) |
|                               | Yes               | 6 (6.3)            | 1 (2.1)     | 1.376 (0.682–2.776) |

Notes: OR = Odds Ratio, CI = Confidence Interval, SD = Standard Deviation, Ref = Reference, HbA1c = Hemoglobin A1C, DM = Diabetes Mellitus, ARMS = Adherence to Refills and Medications Scale, BMI = Body Mass Index

Table 3. Impacts of Metformin-Only and Metformin-sulfonylurea Use on Cognitive Function Decline

| Variable                | Category | Cognitive Function | p-value | OR (95% CI) |
|-------------------------|----------|--------------------|---------|-------------|
| Drug consumption        | Metformin| 45 (63.4)          | 26 (36.6) | 0.373        | Ref            |
|                         | Metformin-sulfonylurea | 50 (70.4) | 21 (29.6) | 1.376 (0.682–2.776) |

Notes: OR = Odds Ratio, CI = Confidence Interval, Ref = Reference
which resulted in the treatment goals not being achieved, also affected the results. In this study, 67.6% of the metformin group and 87.6% of the metformin-sulfonylurea group had an HbA1c level ≥ 7. According to previous studies, high HbA1c levels result in cognitive function decline.\textsuperscript{28,29} The use of sulfonylureas has a high risk of causing hypoglycemia. Cognitive dysfunction in diabetes can be caused by repeated episodes of moderate to a severe hypoglycemia. During an episode of acute hypoglycemia, patients experience impaired global cognitive function and working memory, delayed verbal and visual memory, and impaired visual-spatial and visual-motor skills.\textsuperscript{30}

However, when combined with metformin, sulfonylureas reduce the occurrence of cognitive decline.\textsuperscript{31} Sulfonylureas also have neuroprotective functions, modulating proinflammatory cytokine release and reducing neuronal loss and necrosis.\textsuperscript{32} Although the use of sulfonylureas can cause hypoglycemia, which then triggers cognitive decline, supporting the higher proportion of patients with cognitive decline,\textsuperscript{30} in the metformin-sulfonylurea group, its neuroprotective effects and the addition of metformin may have contributed to the insignificant difference between groups. Since data on which patients experienced hypoglycemia were unavailable, further study is needed to confirm this finding.

This study’s results demonstrate that metformin only and metformin-sulfonylurea did not affect cognitive function. Therefore, to identify the factors that affect cognitive function, a predictive model was created, and a logistic regression was performed using the enter method. The result revealed that age and education affected cognitive function. Previous studies have found that education is a nonmedical protective factor against cognitive decline.\textsuperscript{33,34} The lower the level of education, the higher the risk of cognitive decline. Individuals with higher le-

### Table 4. Logistic Regression for Controlling Confounding Variables

| Model       | Confounding variable | Category          | p-value | OR    | 95% CI   |
|-------------|----------------------|-------------------|---------|-------|----------|
| Crude       | Drug consumption     | Metformin         | 0.373   | Ref   | 0.682–2.776 |
|             | Drug consumption     | Metformin-sulfonylurea | 1.376   |       |          |
| Adjusted\textsuperscript{a} | Drug consumption     | Metformin         | 0.700   | Ref   | 0.512–2.712 |
|             | Drug consumption     | Metformin-sulfonylurea | 1.178   |       |          |
| Age         | ≤65 years old        | Ref               | 0.025   | 1.308–13.748 |
|             | >65 years old        |                   | 4.240   |       |          |
| Sex         | Male                 | Ref               | 0.219   | 0.202–1.442 |
|             | Female               |                   | 0.540   |       |          |
| Education   | >12 years            | Ref               | 0.016   | 1.224–6.893 |
|             | ≤12 years            |                   | 2.904   |       |          |
| BMI         | Skinny–normal (≤25)  | Ref               | 0.462   | 0.583–3.281 |
|             | Overweight–obese (>25)| Ref                | 1.383   |       |          |
| HbA1c       | HbA1c ≤7             | Ref               | 0.320   | 0.222–1.635 |
|             | HbA1c ≥7             |                   | 0.603   |       |          |
| ARMS        | <12                  | Ref               | 0.682   | 0.393–5.912 |
|             | ≥12                  |                   | 1.279   |       |          |
| Adherence   | Adherent             | Ref               | 0.348   | 0.333–5.912 |
|             | Non-adherent         |                   | 1.778   |       |          |
| Hypertension| No                   | Ref               | 0.164   | 0.793–3.882 |
|             | Yes                  |                   | 1.737   |       |          |
| B12 Supplementation | Yes            | Ref               | 0.506   | 0.521–3.742 |
|             | No                   |                   | 1.397   |       |          |
| Adjusted\textsuperscript{b} | Drug consumption     | Metformin         | 0.808   | Ref   | 0.523–2.297 |
|             | Metformin-sulfonylurea | Ref              | 1.096   |       |          |
| Education   | >12 years            | Ref               | 0.098   | 0.890–3.949 |
|             | ≤12 years            |                   | 1.873   |       |          |
| Adherence   | Adherent             | Ref               | 0.040   | 1.036–6.678 |
|             | Non-adherent         |                   | 2.202   |       |          |

\textbf{Notes:} OR = Odds Ratio, CI = Confidence Interval, HbA1c = Hemoglobin A1C, ARMS = Adherence to Refills and Medications Scale, BMI = Body Mass Index

\textsuperscript{a}Adjusted for all variables that had p-value<0.25 in the bivariate analysis or that could theoretically affect cognitive function

\textsuperscript{b}The most precise model.

### Table 5. Effects of Variables on Decline in Cognitive Function

| Variable     | Category       | p-value | OR    | 95% CI    |
|--------------|----------------|---------|-------|-----------|
| Age          | ≤65 years old  | 0.018   | Ref   | 1.271–13.428 |
|              | >65 years old  | 4.151   |       |           |
| Education    | >12 years      | 0.017   | Ref   | 1.196–6.305 |
|              | ≤12 years      | 2.746   |       |           |

\textbf{Notes:} OR = Odds Ratio, CI = Confidence Interval

The use of sulfonylureas has a high risk of causing hypoglycemia. Cognitive dysfunction in diabetes can be caused by repeated episodes of moderate to a severe hypoglycemia. During an episode of acute hypoglycemia, patients experience impaired global cognitive function and working memory, delayed verbal and visual memory, and impaired visual-spatial and visual-motor skills.\textsuperscript{30}
nels of education are not only at lower risk for cognitive distraction, but also show better cognitive performance than those with low education.33

Education is thought to play a role in increasing resistance to neurodegenerative processes. Experiences gained during education, such as continuous exposure to cognitive stimulation and opportunities to gain knowledge and skills, affect an individual’s cognitive ability.34 Furthermore, age is associated with physiological functional decline in various organ systems, including the psychomotor system and cognitive function in the brain. Changes in anatomy and physiology that inevitably occur during aging affect cognitive function.35 The age difference between DM patients can also explain why some experience neurocognitive morbidity that is clinically significant while most are unaffected.

Cognitive decline has been shown to significantly increase morbidity and mortality and reduce the quality of life, increasing the public health burden.36 People with cognitive decline are at risk of having other neurodegenerative diseases, such as Alzheimer’s disease, which increases the cost burden per patient by as much as USD6,784.37 A declines in cognitive function can interfere with self-care management behaviors, such as adherence to medication. As education and age can affect cognitive decline, people in the public health sector should be encouraged to pay more attention to nonmedical factors that affect cognitive decline. For populations with less than 12 years of education, special education sessions and health promotion can be implemented to develop knowledge, attitude, and behavior about the importance of good medication management.

Elderly patients need special attention from health professionals to manage their treatment. Collaboration between health professionals has been shown to improve the quality of patient care in the long term.38 Programs in Indonesian primary health care, such as the Prolanis and Integrated Service Post for Older People/Pos Pelayanan Terpadu Lansia (Posyandu Lansia), can be a means for health providers to encourage the elderly with cognitive decline to visit primary health care facilities to monitor and treat their diseases and achieve optimal quality of life and prevent complications.39,40 At any rate, health professionals are encouraged to work with public health experts to address the effect of medical and nonmedical factors on patient health status.

**Strengths and Limitations**

This study has some limitations, one of which is its cross-sectional design. A cross-sectional design cannot determine the causal factors of the study variables. Second, this study was only conducted at one primary health care. Hence, selection bias might have affected the validity of the results, as the sample was not representa-

tive of the overall population in Indonesia. Moreover, the sample size was limited and predominantly comprised women, thus limiting statistical power.

However, the inclusion and exclusion criteria, including the minimum antidiabetic therapy duration, helped reduce the limitation. The MoCA-Ina instrument used to measure cognitive function also had high validity and reliability. The metformin and metformin-sulfonylurea groups, the most widely used therapies for T2DM in the primary health care, were examined. Therefore, the results could be useful for assessing the safety of antidiabetic therapies in the community. Given the limitations of the study and the widespread use of metformin and its combination with a sulfonylurea, further study is needed.

**Conclusion**

This study does not find a significant difference between the impacts of metformin only and the combination of metformin-sulfonylurea on cognitive function. Even though confounding variables are controlled for, the results are not statistically significant. The factors that most affect cognitive decline are education and age.

**Abbreviations**

T2DM: Type 2 Diabetes Mellitus; MoCA-Ina: Indonesian version of the Montreal Cognitive Assessment; BDI-II: Beck Depression Inventory-II; HbA1c: Hemoglobin A1C; PDC: Proportion of Days Covered; ARMS: Adherence to Refills and Medications Scale; BMI: Body Mass Index.

**Ethics Approval and Consent to Participate**

This study passed an ethical review conducted by the Health Research Ethics Committee in the Faculty of Medicine at Universitas Indonesia (KEPK FK UI; approval number KET-936/UN2.F1/ETIK/PPM.00.02/2021). Research approval was also given by the Special Capital Region of Jakarta Health Office and then forwarded to the South Jakarta Municipality Health Office and the Pasar Minggu Primary Health Care of South Jakarta.

**Competing Interest**

The authors declare that there are no significant competing financial, professional, or personal interests that might have affected the performance.

**Availability of Data and Materials**

The data were not made publicly available, as they contained information that could compromise the privacy of the research participants.

**Authors’ Contribution**

RS contributed to conceptualization, data curation, funding acquisition, investigation, methodology, project administration, supervision, validation, writing, reviewing, and editing. AR contributed to conceptualization, data curation, formal analysis, methodology, supervision,
validation, investigation, writing, reviewing, and editing. All the authors discussed the final results and contributed to the final manuscript. NFS contributed to conceptualization, data curation, methodology, supervision, investigation, writing, reviewing, and editing. PP contributed to conceptualization, methodology, supervision, investigation, writing, reviewing, and editing. HWR contributed to data curation, formal analysis, supervision, writing, reviewing, and editing. The authors also would like to thank all the colleagues, respondents, and Pasar Minggu Primary Health Care staff who helped with the data collection.

Acknowledgment
This study was funded and supported by a Penelitian Disertasi Doktor grant from the Ministry of Education, Culture, Research, and Technology, Republic of Indonesia (NKB-376/UN2.RST/HKP.05.00/2022). The authors gratefully acknowledged the supervisors and colleagues who facilitated this study from start to finish. The authors would also like to thank all the colleagues, respondents, and Pasar Minggu Primary Health Care staff who helped with the data collection.

References
1. Kementerian Kesehatan Republik Indonesia. Tetap produktif, cegah dan atasi diabetes mellitus. Putat Data dan Informasi Kementerian Kesehatan RI; 2020.
2. Varghese SM, Joy N, John AM, George G, Chandy GM, Benjamin AI. Sweet memories or not? a comparative study on cognitive impairment in diabetes mellitus. 2022; 10 (February): 1–7.
3. Hopkins R, Shaver K, Weinstock RS. Management of adults with diabetes and cognitive problems. Diabetes Spectr. 2016; 29 (4): 244–37.
4. Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Series diabetes and brain health 3 understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. 2021; 19.
5. Moore EM, Mander AG, Ames D, Kotelchuc MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013; 36 (10): 2981–7.
6. Porter KM, Ward M, Hughes CF, O’Kane M, Hoey L, McCann A, et al. Hyperglycaemia and metformin use are associated with vitamin deficiency and cognitive dysfunction in older adults. J Clin Endocrinol Metab. 2019; 104 (10): 4837–47.
7. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rassouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 2021; 12: 1–13.
8. Zhang QQ, Li WS, Liu Z, Zhang HL, Ba YG, Zhang RX. Metformin therapy and cognitive dysfunction in patients with type 2 diabetes. Medicine (Baltimore). 2020; 99 (10): e19378.
9. Samaras K, Makkar S, Crawford JD, Kochan NA, Wen W, Draper B, et al. Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney memory and ageing study. Diabetes Care. 2020; 43 (11): 2691–701.
10. Picone P, Nuzzo D, Caruana L, Messina E, Barera A, Vasto S, et al. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin’s effect. Biochim Biophys Acta - Mol Cell Res. 2015; 1853 (5): 1046–59.
11. Lee AK, Rawlings AM, Lee CJ, Gross AL, Huang ES, Sharrett AR, et al. Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia. 2018; 61 (9): 1936–63.
12. Tumininia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer’s disease: role of insulin signalling and therapeutic implications. Int J Mol Sci. 2018; 19 (11): 3306.
13. Olivari BS, Baumgart M, Taylor CA, McGuire LC. Population measures of subjective cognitive decline: a means of advancing public health policy to address cognitive health. Alzheimer’s Dement Transl Res Clin Interv. 2021; 7 (1).
14. Ogston SA, Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of sample size in health studies. Biometrics. 1991; 47 (1): 347.
15. Wu CY, Ouk M, Wong YY, Anita NZ, Edwards JD, Yang P, et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer’s disease, and the role APOE carrier status. Alzheimer’s Dement. 2020; 16 (12): 1665–73.
16. Perkumpulan Endokrinologi Indonesia. Pedoman pencegahan diabetes mellitus tipe 2 dewasa di Indonesia 2015. PB Perkeni. 2020; 46.
17. Morley JE, Morris JC, Berg-Weger M, Borson S, Carpenter BD, del Campo N, et al. Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. J Am Med Dir Assoc. 2015; 16 (9): 731–9.
18. Husein N, Lumempouw S, Ramli Y, Herquanto. Montreal cognitive assessment versi Indonesia mocaina untuk skrining gangguan fungsi kognitif. Neurona. 2010; 27 (4).
19. Nasreddine ZS, Phillips NA, BÃödÃrion V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53 (4): 695–9.
20. Ginthing H, Näring G, Van Der Veld WM, Srisayekti W, Becker ES. Validating the beck depression inventory-II in Indonesia’s general population and coronary heart disease patients. Int J Heal Psychol. 2013; 13 (3): 235–42.
21. Cahyadi H, Prayitno A, Setiawan E. Reliability and validity of adherence to refill and medication scale (ARMS) in Indonesian geriatric population with diabetes; 2015.
22. Anghel LA, Farcas AM, Opren RN. An overview of the common methods used to measure treatment adherence. Med Pharm Reports. 2019; 92 (2): 117–22.
23. Soraya IA, Saurisarti R, Prawiroharjo P, Risni HW. The association between adherence to oral antihyperglycemic agent and HbA1c level. Pharm Sci Res. 2022; 9 (2): 93–101.
24. Søhn D, Shpanskaya K, Lucas JE, Petrella JR, Saykin AJ, Tanzi RE, et al. Sex differences in cognitive decline in subjects with high likelihood of mild cognitive impairment due to Alzheimer’s disease. Sci Rep. 2018; 8 (1): 7490.
25. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men. Neurology. 2010; 75 (10): 889 LP – 897.
26. Soh Y, Lee DH, Won CW. Association between vitamin B12 levels
and cognitive function in the elderly Korean population. Medicine (Baltimore). 2020; 99 (30): e21371.

27. Zhang Q, Li S, Li L, Li Q, Ren K, Sun X, et al. Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016; 8 (12): 798.

28. Silverman JM, Schneider J, Lee PG, Alexander NB, Beeri MS, Guerrero-Berroa E, et al. Associations of hemoglobin A1c with cognition reduced for long diabetes duration. Alzheimer’s Dement Transl Res Clin Interv. 2019; 5: 926–32.

29. Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA1c, diabetes and cognitive decline: the english longitudinal study of ageing. Diabetologia. 2018; 61 (4): 839–48.

30. Vijayakumar T, Sirisha G, Begam F. Mechanism linking cognitive impairment and diabetes mellitus. Eur J Appl Sci. 2012; 4 (1): 1–05.

31. Vijayakumar PRA. Comparison of different classes of oral antidiabetic. 2019; 10 (7): 3455–60.

32. Hussien NR, Al-Naimi MS, Rasheed HA, Al-Kuraishy HM, Ali AG. Sulfonylurea and neuroprotection: the bright side of the moon. J Adv Pharm Technol Res. 2018; 9 (4): 120–3.

33. Lövdén M, Fratiglioni L, Glymour MM, Lindenberger U, Tucker-Drob EM. Education and cognitive functioning across the lifespan. Psychol Sci Public Interes. 2020; 21 (1): 6–41.

34. Jansen MG, Geerligs L, Claassen JAHR, Overdorp EJ, Brazil IA, Kessels RPC, et al. Positive effects of education on cognitive functioning depend on clinical status and neuropathological severity. Front Hum Neurosci. 2021; 15: 1–10.

35. Kartikasari D, Ariwinanti D, Hapsari A. Gambaran pengetah kesehat reproduksi siswa SMK Wisnuwardhana Kota Malang. Preventia : The Indonesian Journal of Public Health. 2019; 4 (1): 34–41.

36. Paul KC, Ling C, Lee A, To TM, Cockburn M, Haan M, et al. Cognitive decline, mortality, and organophosphorus exposure in aging Mexican Americans. Environ Res. 2018; 160: 132–9.

37. Leibson CL, Long KH, Ransom JE, Roberts RO, Hass SL, Duhig AM, et al. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. Alzheimer’s Dement. 2015; 11 (8): 917–32.

38. Sorensen M, Groven KS, Gjelsvik B, Almendingen K, Garnweitner-Holme L. The roles of healthcare professionals in diabetes care: a qualitative study in Norwegian general practice. Scand J Prim Health Care. 2020; 38 (1): 12–23.

39. Akbar JM, Gondodiputro S, Raksanagara AS. Elderly satisfaction on chronic disease management program at public health center, Bandung City, West Java, Indonesia. Int J Integr Heal Sci. 2020; 8 (1): 14–21.

40. Fatmah F. Training program to support posbindu cadre knowledge and community health centre staff in the Geriatric Nutrition Service. ASEAN J Community Engagem. 2020; 4 (2): 500–18.